Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
2.040
-0.040 (-1.92%)
Jun 11, 2025, 4:00 PM - Market closed
Mainz Biomed Employees
As of December 31, 2024, Mainz Biomed had 26 total employees, including 19 full-time and 7 part-time employees. The number of employees decreased by 45 or -63.38% compared to the previous year.
Employees
26
Change (1Y)
-45
Growth (1Y)
-63.38%
Revenue / Employee
$34,384
Profits / Employee
-$832,718
Market Cap
6.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -45 | -63.38% |
| Dec 31, 2023 | 71 | 7 | 10.94% |
| Dec 31, 2022 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MYNZ News
- 1 day ago - Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewsWire
- 23 days ago - Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewsWire
- 26 days ago - Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Enters into Technology Partnership with EDX Medical Group - GlobeNewsWire
- 6 weeks ago - Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewsWire
- 2 months ago - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 3 months ago - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewsWire